| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
23009 |
| Drug |
Durvalumab |
| Brand |
Imfinzi® |
| Indication |
Durvalumab in combination with gemcitabine and cisplatin is indicated for the first-line treatment of adults with unresectable or metastatic biliary tract cancer. |
| Rapid review commissioned |
20/02/2023 |
| Rapid review completed |
16/03/2023 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of durvalumab used in combination with gemcitabine and cisplatin compared with the current SOC (gemcitabine and cisplatin). |
| Full pharmacoeconomic assessment commissioned by HSE |
29/03/2023 |
| Pre-submission consultation with Applicant |
06/06/2023 |
| Full submission received from Applicant |
04/10/2023 |
| Preliminary review sent to Applicant |
12/08/2024 |
| NCPE assessment re-commenced |
10/09/2024 |
